Rocuronium
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Morbid Obesity
Conditions
Morbid Obesity
Trial Timeline
May 1, 2016 → Oct 1, 2017
NCT ID
NCT02703909About Rocuronium
Rocuronium is a approved stage product being developed by Merck for Morbid Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT02703909. Target conditions include Morbid Obesity.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02812186 | Approved | Completed |
| NCT02703909 | Approved | Completed |
| NCT02553629 | Approved | Completed |
| NCT02320734 | Approved | Completed |
| NCT02025075 | Pre-clinical | Completed |
| NCT00902070 | Pre-clinical | Completed |
Competing Products
7 competing products in Morbid Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Approved | 85 |
| Posaconazole Injection [Noxafil] 300mg + Posaconazole Injection [Noxafil] 400mg | Merck | Approved | 85 |
| Placebo + IBI362 | Innovent Biologics | Phase 3 | 76 |
| Supemtek® + Vaxigriptetra® | Sanofi | Phase 3 | 76 |
| Molindone | Supernus Pharmaceuticals | Phase 2 | 47 |
| SPN-810M | Supernus Pharmaceuticals | Phase 1 | 28 |
| SPN-810 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |